A detailed history of Envestnet Asset Management Inc transactions in Exelixis, Inc. stock. As of the latest transaction made, Envestnet Asset Management Inc holds 170,336 shares of EXEL stock, worth $5.67 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
170,336
Previous 143,055 19.07%
Holding current value
$5.67 Million
Previous $3.21 Million 37.52%
% of portfolio
0.0%
Previous 0.0%

Shares

26 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 06, 2024

BUY
$21.96 - $27.6 $599,090 - $752,955
27,281 Added 19.07%
170,336 $4.42 Million
Q2 2024

Aug 08, 2024

SELL
$20.34 - $23.73 $252,093 - $294,109
-12,394 Reduced 7.97%
143,055 $3.21 Million
Q1 2024

May 13, 2024

BUY
$20.17 - $23.93 $248,030 - $294,267
12,297 Added 8.59%
155,449 $3.69 Million
Q4 2023

Feb 13, 2024

BUY
$19.25 - $24.13 $441,633 - $553,590
22,942 Added 19.08%
143,152 $3.43 Million
Q3 2023

Nov 13, 2023

SELL
$19.04 - $22.74 $350,412 - $418,506
-18,404 Reduced 13.28%
120,210 $2.63 Million
Q2 2023

Aug 04, 2023

BUY
$18.17 - $20.48 $213,224 - $240,332
11,735 Added 9.25%
138,614 $2.65 Million
Q1 2023

May 11, 2023

SELL
$16.3 - $19.41 $398,746 - $474,826
-24,463 Reduced 16.16%
126,879 $2.46 Million
Q4 2022

Feb 07, 2023

SELL
$14.96 - $17.39 $170,409 - $198,089
-11,391 Reduced 7.0%
151,342 $2.43 Million
Q3 2022

Nov 10, 2022

SELL
$15.68 - $22.27 $76,518 - $108,677
-4,880 Reduced 2.91%
162,733 $2.55 Million
Q2 2022

Aug 03, 2022

BUY
$17.44 - $23.16 $182,073 - $241,790
10,440 Added 6.64%
167,613 $3.49 Million
Q1 2022

May 04, 2022

BUY
$17.03 - $22.67 $662,790 - $882,293
38,919 Added 32.91%
157,173 $3.56 Million
Q4 2021

Feb 04, 2022

SELL
$15.84 - $21.88 $391,707 - $541,070
-24,729 Reduced 17.3%
118,254 $2.16 Million
Q3 2021

Oct 07, 2021

BUY
$16.3 - $21.14 $78,924 - $102,359
4,842 Added 3.51%
142,983 $3.02 Million
Q2 2021

Aug 04, 2021

BUY
$17.95 - $25.56 $215,687 - $307,128
12,016 Added 9.53%
138,141 $2.52 Million
Q1 2021

May 04, 2021

SELL
$20.53 - $25.22 $580,218 - $712,767
-28,262 Reduced 18.31%
126,125 $2.85 Million
Q4 2020

Feb 02, 2021

SELL
$18.39 - $24.8 $120,197 - $162,092
-6,536 Reduced 4.06%
154,387 $3.1 Million
Q3 2020

Oct 09, 2020

SELL
$20.67 - $26.94 $232,909 - $303,559
-11,268 Reduced 6.54%
160,923 $3.94 Million
Q2 2020

Jul 08, 2020

SELL
$16.46 - $27.42 $591,605 - $985,529
-35,942 Reduced 17.27%
172,191 $4.09 Million
Q1 2020

Apr 23, 2020

BUY
$14.46 - $21.8 $430,994 - $649,770
29,806 Added 16.71%
208,133 $3.58 Million
Q4 2019

Feb 11, 2020

BUY
$15.15 - $18.89 $846,991 - $1.06 Million
55,907 Added 45.67%
178,327 $3.14 Million
Q3 2019

Oct 17, 2019

BUY
$17.68 - $22.65 $1,555 - $1,993
88 Added 0.07%
122,420 $2.17 Million
Q2 2019

Aug 02, 2019

SELL
$18.93 - $24.75 $1.85 Million - $2.42 Million
-97,740 Reduced 44.41%
122,332 $2.61 Million
Q1 2019

May 10, 2019

BUY
$19.6 - $24.76 $2.83 Million - $3.58 Million
144,409 Added 190.86%
220,072 $5.24 Million
Q4 2018

Feb 13, 2019

BUY
$13.65 - $21.8 $1.03 Million - $1.65 Million
75,663 New
75,663 $1.49 Million
Q3 2017

Nov 13, 2017

SELL
$23.35 - $29.24 $25,661 - $32,134
-1,099 Closed
0 $0
Q2 2017

Aug 14, 2017

BUY
N/A
1,099
1,099 $27,000

Others Institutions Holding EXEL

About EXELIXIS, INC.


  • Ticker EXEL
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 321,832,000
  • Market Cap $10.7B
  • Description
  • Exelixis, Inc., an oncology-focused biotechnology company, focuses on the discovery, development, and commercialization of new medicines to treat cancers in the United States. The company's products include CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ ...
More about EXEL
Track This Portfolio

Track Envestnet Asset Management Inc Portfolio

Follow Envestnet Asset Management Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Envestnet Asset Management Inc, based on Form 13F filings with the SEC.

News

Stay updated on Envestnet Asset Management Inc with notifications on news.